HCPs
New Page
Historie pacjentów
Zaangażować się
Dom
Who we are
What we do
Events
Wczesna diagnoza
NICE
Filmy
Copy of Reports
Zasoby
Sklep
Skontaktuj się z nami
Menu
Alectinib is a 2nd generation TKI developed by Roche. The recommended dose is 600mg taken twice daily. Along with Brigatinib, Alectinib is the usual first line treatment for newly diagnosed ALK-positive lung cancer patients